MEDP at a glance
Medpace Holdings Inc (MEDP, SEC CIK 1668397) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 22, 2026, an 8-K current report on October 21, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Medpace Holdings Inc (MEDP) reported revenue of $2.5 billion (up 20.0% from FY2024) and net income of $451.1 million. Diluted EPS was $15.28.
- As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Medpace Holdings Inc (MEDP) shares worth $7.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by EWALD STEPHEN P on October 29, 2026 of 1,245 shares at $690.00 per share.
- In the last 90 days, MEDP insiders reported 0 open-market purchases ($0) and 19 open-market sales ($147.2M) on Form 4, a net sale of $147.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.5B
- +20.0% vs prior year
- Insiders · 90 days
- 0 buys · 19 sells
- Net −$147.2M
- 13F holders
- 39 funds
- $7.3B · +0 vs prior quarter
- Latest 8-K
- Oct 21, 2026
- Item 8.01 · Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Full-service Phase I-IV CRO, serving biotech, pharmaceutical and medical device companies across major therapeutic areas
- ClinTrak-enabled clinical trial management, integrating real-time study metrics with operating procedures
- Expanded laboratory platform: four Central Laboratory locations across the U.S., Belgium, China and Singapore
- Strategic positioning toward small and mid-sized biopharma, emphasizing disciplined execution, therapeutic expertise and timely delivery
- Customer risk-sharing arrangements, including strategic investments, flexible payment terms and fee financing capabilities
Management Discussion & Analysis
- Revenue $2.530B, up 20.0% YoY, driven by Metabolic, Oncology and Central Nervous System activity
- Operating margin 21.1% vs 21.2%, net income $451.1M vs $404.4M
- Best performing areas: Metabolic, Oncology and Central Nervous System, supporting revenue growth
- Operating cash flow $713.2M, capex 1.24% of revenue, share repurchases $912.9M, no indebtedness
- Outlook: organic growth and selective bolt-on acquisitions, with liquidity sufficient for 12 months, but future cash flow and borrowing availability uncertain
Risk Factors
- Customer concentration: top ten customers generated approximately 35.1% of 2025 net revenue
- Small-biopharma exposure: 82% of 2025 net revenue came from customers potentially constrained by limited capital
- Fixed-fee contract overruns: majority of Phase I-IV contracts expose Medpace to underpricing and unrecovered costs
- Operational dependency: ClinTrak and third-party laboratories, logistics providers, drug depots and contract personnel support service delivery
- AI disruption: inadequate generative-AI controls could cause delays or errors in customer offerings
AI summary of the MEDP 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $716.0M, up 8.5% YoY from $659.9M, driven by Metabolic, Oncology and CNS
- Operating margin 23.1% vs 21.5% YoY, based on operating income of $165.5M and revenue of $716.0M
- Best-performing therapeutic areas: Metabolic, Oncology and CNS, with no individual revenue figures disclosed
- Cash $705.3M vs $497.0M at December 31, 2025, operating cash flow $530.4M for nine months
- Nine-month share repurchases $294.7M, with $527.0M authorization remaining; new $1.0B authorization approved October 20, 2026
Risk Factors
- No significant changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward risks include operational, regulatory, competitive, market, and financial exposures disclosed in the 2025 Form 10-K
AI summary of the MEDP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Prior authorization terminated October 20, 2026, with $527.0 million unused
- New $1.0 billion repurchase authorization runs through December 31, 2028
Item EX-99.1: Item EX-99.1
- Q3 revenue $716.0M, up 8.5%, with net new awards $873.4M, up 10.6%, supporting continued demand
- Backlog $3.167B, up 5.6%, but 23.8% conversion rate highlights reliance on execution and timing
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Press release available as Exhibit 99.1, containing the detailed operating and financial figures
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Full earnings release available in Exhibit 99.1, containing the detailed operating and financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $707.3M, up 17.2%, with backlog conversion rate 24.1%
- Net new awards $795.7M, up 28.2%, producing 1.13x book-to-bill and supporting future revenue
AI summaries of MEDP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MEDP
Don't miss the next MEDP filing
- Alerts as it files. A push when MEDP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MEDP, by share count.
- Ask anything. An AI agent that reads every MEDP filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| EWALD STEPHEN P | Sell | Oct 29, 2026 | 1,245 | $690.00 |
| BURWIG SUSAN E | Sell | Oct 27, 2026 | 3,940 | $677.00 |
| BURWIG SUSAN E | Sell | Oct 26, 2026 | 16,060 | $677.00 |
| BURWIG SUSAN E | M | Oct 26, 2026 | 328 | - |
| BURWIG SUSAN E | M | Oct 26, 2026 | 328 | $166.73 |
| BURWIG SUSAN E | M | Oct 21, 2026 | 2,700 | $166.73 |
| BURWIG SUSAN E | M | Oct 21, 2026 | 2,700 | - |
| BURWIG SUSAN E | M | Oct 12, 2026 | 3,000 | $166.73 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.1B | $2.5B |
| Operating Income | - | $446.9M | $534.9M |
| Net Income | $282.8M | $404.4M | $451.1M |
| Op. Margin | - | 21.2% | 21.1% |
| Net Margin | - | 19.2% | 17.8% |
| Balance Sheet | |||
| Total Assets | $1.7B | $2.1B | $2.0B |
| Equity | - | $825.5M | $459.1M |
| ROE | - | 49.0% | 98.3% |
| Per Share | |||
| EPS | $8.88 | $12.63 | $15.28 |
| Cash Flow | |||
| Operating CF | - | $608.8M | $713.2M |
| CapEx | $36.6M | $36.5M | $31.4M |
Source: XBRL data in Medpace Holdings Inc (MEDP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MEDP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 39 | $7.28B |
| Q2 2026 | 39 | $6.64B |
| Q1 2026 | 41 | $5.29B |
| Q4 2025 | 37 | $6.19B |
| Q3 2025 | 37 | $5.68B |
| Q2 2025 | 33 | $3.47B |
| Q1 2025 | 30 | $2.68B |
| Q4 2024 | 26 | $2.54B |
- AQR Capital Management+117.7K (+9%)
- BlackRock+64.7K (+3%)
- Citigroup+54.4K (+43%)
- Bridgewater Associates LP+41.9K (+269%)
- D.E. Shaw & Co+39.1K (+17%)
- T. Rowe Price Group−933.4K (-45%)
- Goldman Sachs Group−122.2K (-49%)
- Invesco Ltd−77.7K (-13%)
- Vanguard Portfolio Management LLC−48.1K (-4%)
- JPMorgan Chase & Co−41.7K (-19%)
- FMR LLC (Fidelity)−54.2K
- Equitable Holdings Inc−1.5K
- Marex Group plc−411
- ASSOCIATED BANC-CORP−386
Source: 13F-HR filings on SEC EDGAR (aggregated from 282 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MEDP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Oct 28, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 10-Q | Oct 22, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 21, 2026 | - | Analysis | - |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
MEDP SEC filings: frequently asked questions
Are MEDP insiders buying or selling?
In the last 90 days, Medpace Holdings Inc (MEDP) officers, directors and 10% owners reported no open-market purchases and 19 open-market sales worth $147.2 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MEDP stock?
As of September 30, 2026, the largest Medpace Holdings Inc (MEDP) holders among the 13F filers tracked by SignalX were BlackRock ($1.6 billion), AQR Capital Management ($863.2 million), T. Rowe Price Group ($709.2 million), Vanguard Portfolio Management LLC ($677.4 million), Vanguard Capital Management LLC ($627.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MEDP's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Medpace Holdings Inc (MEDP) reported revenue of $2.5 billion (up 20.0% from FY2024) and net income of $451.1 million. Diluted EPS was $15.28. The figures come from the XBRL data in the 10-K.
What are the main risks in MEDP's latest 10-K?
In the 10-K filed February 10, 2026, Medpace Holdings Inc (MEDP) flagged: Customer concentration: top ten customers generated approximately 35.1% of 2025 net revenue. Small-biopharma exposure: 82% of 2025 net revenue came from customers potentially constrained by limited capital. (AI summary of the Risk Factors section.)
What did MEDP report in its latest 8-K?
Medpace Holdings Inc (MEDP) filed an 8-K on October 21, 2026 reporting Item 8.01 (Other Events) and Item 2.02 (Results of Operations and Financial Condition). Prior authorization terminated October 20, 2026, with $527.0 million unused.
What are the latest MEDP SEC filings?
Medpace Holdings Inc (MEDP) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 22, 2026, an 8-K current report on October 21, 2026 and a Form 4 insider filing on November 2, 2026.
What is MEDP's SEC CIK number?
Medpace Holdings Inc (MEDP)'s SEC Central Index Key (CIK) is 1668397. EDGAR lists every MEDP filing under that number.
Ask anything about MEDP
The research agent reads MEDP's filings, financials, insider trades and 13F holders, then answers with sources.